NCT06435013

Lenvatinib vs Bevacizumab Plus ICIs and HAIC in Unresectable HCC

Lenvatinib Versus Bevacizumab Combined With Immune Checkpoint Inhibitors and Hepatic Arterial Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Retrospective, Multi-center, and Propensity Score Matching Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 208 (actual)
• Sponsor: Sun Yat-sen University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Previous studies had suggested hepatic arterial infusion chemotherapy (HAIC) combined with immune checkpoint inhibitors (ICIs) and anti-angiogenic drugs had promising anti-tumor activity in unresectable hepatocellular carcinoma (HCC). Two kinds of anti-angiogenic drugs (tyrosine kinase inhibitors \[lenvatinib\] and anti-VEGF antibody \[bevacizumab\]) were applied in first-line treatment of unresectable HCC. However, little is known about the difference of efficacy and safety between lenvatinib (LenHAP) or bevacizumab (BevHAP) combined with ICIs and HAIC in unresectable HCC.

Conditions

• Hepatocellular Carcinoma
• Lenvatinib

Interventions

Type	Name	Description
DRUG	Lenvatinib	Lenvatinib combined with hepatic arterial infusion chemotherapy and PD-1/PD-L1;

Timeline

• Start date: 2023-12-01
• Primary completion: 2024-03-01
• Completion: 2024-05-20
• First posted: 2024-05-30
• Last updated: 2024-05-30

Locations

1 site across 1 country: China